- Home
- SLMT vs LTRN Comparison
SLMT vs LTRN Comparison
Compare SLMT & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLMT | LTRN |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.8M | 46.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SLMT | LTRN |
|---|---|---|
| Price | $5.23 | $2.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 86.9K | ★ 184.0K |
| Earning Date | 06-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $1.11 |
| 52 Week High | $24.05 | $5.74 |
Technical Indicators
Market Signals| Indicator | SLMT | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 51.57 | 38.25 |
| Support Level | $4.35 | $2.49 |
| Resistance Level | $5.65 | $3.09 |
| Average True Range (ATR) | 0.63 | 0.35 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 30.37 | 2.80 |
Price Performance
Historical ComparisonAbout SLMT Brera Holdings PLC Class B Ordinary Shares
Solmate Infrastructure Public Ltd is a Solana-based crypto infrastructure company with a strategic focus on Abu Dhabi. The group builds high-performance validators that lower latency, expand network reach, and position Abu Dhabi as a world-wide hub for Solana infrastructure. The company creates value by working with its partners to build infrastructure and real hardware for the crypto revolution. Its cutting-edge Solana staking infrastructure will help drive the adoption of the network in the Middle East.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.